Cargando…
Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain – Study protocol for a randomized double-blind controlled study
BACKGROUND: Tumor necrosis factor inhibitors (TNFi) signify a major advance in the treatment of rheumatoid arthritis (RA). However, treatment success initially remains uncertain as approximately half of the patients do not respond adequately to TNFi. Thus, an unmet need exists to better predict ther...
Autores principales: | Schenker, H.M., Tascilar, K., Konerth, L., Sergeeva, M., Prade, J., Strobelt, S., Kleyer, A., Simon, D., Mendez, L., Hagen, M., Schönau, V., Hueber, A., Roesch, J., Dörfler, A., Hess, A., Schett, G., Rech, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144682/ https://www.ncbi.nlm.nih.gov/pubmed/34041413 http://dx.doi.org/10.1016/j.conctc.2021.100770 |
Ejemplares similares
-
5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017) -
Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis
por: Hum, Ryan M, et al.
Publicado: (2022) -
Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018) -
Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015) -
Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga, Sriya, et al.
Publicado: (2014)